

Corporate Presentation

Unither Pharmaceuticals:

Global Pharmaceutical CDMO specialized in sterile and non-sterile liquid forms to simplify the lives of patients

2023



Unither Pharmaceuticals is a global subcontractor specializing in the development and manufacturing of health products.

With nearly 30 years of experience, our CDMO has become the world leader in Blow-Fill-Seal technology, with an industrial presence on four continents and products sold in more than 100 countries.



Vision, Mission, Promise & Values



Our Vision

We want to be recognized as a provider of affordable, innovative, and easy-to-use health solutions that simplify the lives of patients around the world



Our promise

To consider patients needs in order to make successful products for our pharmaceutical customers



Our mission

To deliver innovative, sustainable and competitive solutions to our customers



Our values

Courage; Innovation; Respect; Responsibility; Trust





Our Leadership team



Eric GOUPIL
President



Jean-François HILAIRE CEO



Eric CHESNEL
Commercial & Licensing
Director



Nathalie MASSON
Innovation &
Development Director



Perrine MILLEREUX
Human Ressources Director



Jean-Pierre LUX
Industrial Director



Benoît FLAMMANGFinancial Director



Alexandre ROCHEREAU
Chief Information Officer






Our History


01- Unither

Pharmaceuticals





Pooling of funds



Management








Revenues & Employees







Our Mission 01- Unither Pharmaceuticals

We offer solutions that are...





Long-term Partnership



...competitive

Pure-player CDMO



...innovative

Health Solutions
Architect



Business model

cystomer Development costs & risks **Contract Development Contract Manufacturing** from pre-clinical to commercial **Full-service CDMO Co-Development** from pre-formulation to industrial with our customers batches, including clinical batches Chither Development costs & risks **Turnkey Products & Dossiers** for out-licensing **OUR PRODUCT LIST**

02- Types of collaboration



Global organization Our Plants






Office



Innovation & Development

Global reach #100 countries

Industrial Footprint on **4 continents** Products sold in more than **100 countries** (France, USA, Brazil, China)



Technology expertise

Sterile/aseptic liquids

Blow-Fill-Seal Worldwide Leader
5 billion unit doses capacity



Blow-Fill-Seal



Preservative-free Multidose



Multidose with preservatives

Non-sterile liquids

Liquid Stick-Pack Pioneer 600 million unit doses capacity



Stick-Packs



Bottles



Sprays

03- Technologies





1

Therapeutic areas

UNITHER UNITHER UNITHER

03- Technologies

Sterile liquids









& Others: Buccal, Otic, Topical

Non-Sterile liquids









& Others: Cosmetics, Central nervous system, Orphan diseases, Food supplement



Global **Organization**

Bordeaux Amiens Coutances Gannat **Colomiers** Rochester **Barretos** Butantã Nanjing **((** Sterile liquids Blow-Fill-Seal **V** V V V V Preservative-V free Multidose Multidose with **V V** preservatives Non-Sterile liquids Liquid V V Stick-Packs **Bottles V** V **v**) Sprays Others Suppositories & V V Pessaries Tablets & **V V V** Capsules (**V**) Tubes

03- Technologies

Authorizations & Regulatory

Health authorities

























China GMP, Turkye, Libya, Belarus, Saudi Arabia, Iran, etc.

Regulatory compliance







ecovadis





Our CSR strategy focuses on three key areas: reducing our environmental impact, improving the health, safety and quality of life of our employees, and increasing access to health solutions.





To Summarize



Contract development & manufacturing organization
Focused on key pharmaceutical niches



Worldwide leader on BFS technology
5 billion unit doses capacity



Liquid Stick-Pack pioneer 600 million unit doses capacity



Global CDMO

Industrial Footprint on **4 continents**Products sold in more **than 100 countries**(France, USA, Brazil, China)



Growing business

€371 million budget and 2000 employees in 2022



Private company

26% owned by management **74% private** equity fund



Thank you for your attention

Please, feel free to contact us

contact@unither-pharma.com Tel. +33 (0)1 44 63 51 70





www.unither-pharma.com